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Tumours have at least two mechanisms that can alter dendritic cell (DC) maturation and function. The first affects the ability of
haematopoietic progenitors to differentiate into functional DCs; the second affects their differentiation from CD14þ monocytes,
promoting an early but dysfunctional maturation. The aim of this study was to evaluate the in vivo relevance of these pathways in
breast cancer patients. For this purpose, 53 patients with invasive breast cancer were compared to 68 healthy controls. To avoid
isolation or culture procedures for enrichment of DCs, analyses were directly performed by flow cytometry on whole-blood samples.
The expression of surface antigens and intracellular accumulation of regulatory cytokines upon LPS stimulation were evaluated. The
number of DCs, and in particular of the myeloid subpopulation, was markedly reduced in cancer patients (Po0.001). Patient DCs
were characterized by a more mature phenotype compared with controls (P¼0.016), and had impaired production of IL-12
(Po0.001). These alterations were reverted by surgical resection of the tumour. To investigate the possible role of some tumour-
related immunoactive soluble factors, we measured the plasmatic levels of vascular endothelial growth factor, IL-10 and spermine. A
significant inverse correlation between spermine concentration and the percentage of DCs expressing IL-12 was found. Evidence was
also obtained that in vitro exposure of monocyte-derived DCs to spermine promoted their activation and maturation, and impaired
their function. Taken together, our results suggest that both the above-described mechanisms could concomitantly act in breast
cancer to affect DC differentiation, and that spermine could be a mediator of dysfunctional maturation of DCs.
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Dentritic cells (DCs) represent the most potent professional
antigen-presenting cells, because of their widespread localisation
in all sites of antigen entry, their ability to process tumour antigens
and present them on HLA class II as well as class I molecules, their
high expression of costimulatory molecules, and their production
of regulatory cytokines (Rescigno et al, 1999; Larsson et al, 2001).
Owing to the unique ability of DCs to stimulate naive T
lymphocytes and therefore to initiate tumour-specific cytotoxic
immune responses (Croft et al, 1992), these cells are critical
elements of antitumour immunity induction.
Tumours have at least two mechanisms by which they can alter
DC maturation and function. The first one affects the ability of
haematopoietic progenitor cells to differentiate into functional
DCs during the early stages of their maturation. In vitro, it has
been demonstrated that factors that can be produced by tumour
cells, including vascular endothelial growth factor (VEGF), M-CSF
and IL-6, inhibit DC maturation from CD34þ cells (Gabrilovich
et al, 1996; Menetrier-Caux et al, 1998). In vivo, tumour-derived
VEGF has been proposed as the most likely factor to affect the
early stage of DC maturation in the bone marrow (Ishida et al,
1998; Gabrilovich et al, 1999). In breast, head and neck and lung
cancer, the inhibitory effects of VEGF on DC differentiation have
been described to cause a decrease of PB DCs closely associated
with accumulation of immature myeloid cells lacking markers of
mature haematopoietic cells (Almand et al, 2000). The second
mechanism by which tumours can alter DC maturation affects
their differentiation from CD14þ monocyte precursors. This
pathway, that is also mediated by soluble tumour-derived factors,
acts by promoting an early but dysfunctional maturation of DCs.
In particular, it has been demonstrated in vitro that the addition of
tumour supernatants during DC differentiation from PB mono-
cytes induces the generation of DCs that are more mature and that
display a diminished capacity to take up antigens and to produce
regulatory cytokines, and do not develop full allostimulatory
activity (Kiertscher et al, 2000).
Whereas several tumour-derived soluble factors are known to
affect DC differentiation from CD34þ cells (Gabrilovich et al,
1996; Menetrier-Caux et al, 1998), the mediators leading to the
premature phenotypic maturation of monocyte-derived DCs still
remain to be determined. A number of tumour-derived factors
with the capacity of altering the maturation of CD34þor
CD14þprecursors, including VEGF, TGF-b, IL-10 and PGE2, have
been excluded to be implicated in this pathway (Kiertscher et al,
2000). Polyamines are potential candidates, because they are
important modulators of immune functions and occur at high
concentrations in actively proliferating tissues (Seiler and Atanas-
sov, 1994; Zhang et al, 1997). Spermine, in particular, has been
suggested to contribute to the decreased immune reaction against
tumours. In fact, elevated levels of spermine have been reported in
the plasma and urine of patients with tumours, including breast Received 17 March 2003; revised 7 July 2003; accepted 8 July 2003
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spermine has recently been demonstrated to inhibit the production
of IL-12 by in vitro-stimulated macrophages (Hasko ` et al, 2000).
The aim of the present study was to evaluate the in vivo
relevance of the above-described pathways followed by tumours to
alter DC maturation and function. For this purpose, we
enumerated and functionally characterised DCs in the peripheral
blood of patients with breast cancer. To avoid isolation or culture
procedures for the enrichment of DCs that may induce the
selection of particular cell subsets and/or phenotypic and
functional modifications of DCs present in the sample, our
analyses were directly performed by flow cytometry on whole-
blood samples. Our results confirmed that the number of DCs is
decreased in the peripheral blood of cancer patients. In particular,
the myeloid CD11cþ subpopulation of DCs was dramatically
reduced. Furthermore, DCs from cancer patients were charac-
terised by a more mature immunophenotype compared with
controls, and had impaired production of IL-12. Therefore, they
appeared affected by a dysfunctional maturation similar to that
induced in vitro by tumour supernatants during DC maturation
from monocyte precursors (Kiertscher et al, 2000). These
alterations in the maturation of DCs were completely reverted by
surgical resection of the tumour. In vitro evidence provided in this
study suggests that spermine could be a possible mediator by
which breast cancer affects DC functions.
MATERIALS AND METHODS
Patient selection
In all, 53 patients aged 29–86 (mean 58) years with histologically
confirmed invasive breast cancer were enrolled into the study.
Peripheral venous heparinised blood samples were obtained from
all patients before any surgical, chemotherapic and/or radiant
treatment. Staging was performed in accordance with the
American Joint Committee on Cancer criteria (Sobin and
Witterkind, 2002). A total of 15 patients had stage I disease, 16
had stage IIA and 22 had stage IIB. In all 68, sex- and age-matched
healthy donors (range 24–88, mean 55 years) were used as
controls. Six age-matched patients with benign tumour of the
breast and six with in situ breast carcinoma were also included.
Informed consent was obtained from all individuals.
Immunophenotypic analysis and counting of peripheral
blood cells
Whole peripheral blood samples (1 10
6 cells in 100mltest
 1)
were analysed by direct immunofluorescence using three-colour
stainings with mAbs directly conjugated with fluorochromes FITC,
PE and PerCP. Erythrocytes were lysed after staining, using FACS
Lysing Solution (Becton Dickinson, San Jose, CA, USA) according
to the manufacturer’s instructions. DCs were identified as positive
for anti-HLA-DR PerCP (Becton Dickinson) and negative for a
mixture of FITC-conjugated mAbs (Caltag Laboratoires, Burlin-
game, CA, USA) specific for lineage markers on T cells (CD3), B
cells (CD19, CD20), NK cells (CD16) and monocytes (CD14). Anti-
CD11c PE (Caltag Laboratoires) or anti-IL3Ra (CD123) PE
(Pharmingen, San Diego, CA, USA) were used for identification
of myeloid and plasmacytoid DC subpopulations, respectively.
Cells labelled with isotype control mAbs were included to
determine background fluorescence. All operations were done at
41C. Three-colour analysis was performed using a FACScan flow
cytometer (Becton Dickinson) using CellQuest software (Macin-
tosh). Since PB DCs are characterised by forward scatter (FSc)
similar to monocytes and side scatter (SSc) similar to lymphocytes
(Upham et al, 2000), an acquisition gate was established based on
FSc and SSc, which included both the lymphocyte and monocyte
populations (mononuclear cells), but excluded most granulocytes
and debris. Owing to the low frequency of lineage-/HLA-DRþ
cells, we routinely collected 50000 events to visualise and gate on
this population more easily. Conventional haematological para-
meters in comparable blood samples were also measured using an
ADVIA 120 automated haematology analyser (Bayer Diagnostics,
Basingstoke, Berkshire, UK). Estimates of the absolute numbers of
DCs in blood were calculated from the proportion of DCs recorded
in the mononuclear gate determined by flow cytometry multiplied
by absolute mononuclear cell count. The assumption was that
lymphocytes and monocytes, as determined by the haematology
cell counter, together constitute the mononuclear fraction
identified by flow cytometry. PE-conjugated anti-CD80, CD83,
CD86 (Pharmingen) and CD119 (Caltag Laboratoires) were used to
evaluate the activation and maturation states of Lin-/HLA-DRþ
DCs, directly in fresh whole-blood samples or in blood samples
diluted vv
 1 in RPMI 1640 medium (Euroclone, Wetherby, West
York, UK), and incubated for 5h with or without LPS (100ngml
 1;
from Escherichia coli, serotype 055:B5; Sigma). The frequency of
DC precursors in the peripheral blood was determined by direct
immunofluorescent staining with FITC-conjugated anti-CD34 or
CD14 antibodies (Caltag Laboratoires).
Cytoplasmic cytokine expression
Expression of the cytokines IL-12 and IL-10 in the cytoplasm of PB
Lin-/HLA-DRþDCs was determined by flow cytometry. Whole
peripheral blood (500ml) supplemented with 500ml of RPMI 1640
medium was incubated for 5h with or without 100ngml
 1 LPS.
The protein transport inhibitor brefeldin A (BFA) (10mgml
 1;
Sigma, St Louis, MO, USA) was added during the last 4h, to allow
intracellular accumulation of cytokines. Incubation was performed
at 371C in a 5% CO2 humid atmosphere in a sterile environment.
Doses of BFA and LPS, and incubation times, were optimised in
preliminary experiments. At the end of the incubation period,
samples were aliquoted and labelled with appropriate combina-
tions of mAbs for staining of surface markers. Cells were then
fixed, permeabilised and stained with cytokine-directed mAbs
anti-IL-12 PE and anti-IL-10 PE (Caltag Laboratoires), using the
Fix & Perm reagent (Caltag Laboratoires) (Almeida et al, 1999;
Bueno et al, 2001). Cytokine-directed mAbs were used at
saturating concentrations and conditions. Samples stimulated
under the same culture conditions in the absence of BFA showed
undetectable cytokine levels. Cells labelled with isotype control
mAbs were included to determine background fluorescence. The
evaluation of cytokine production was based on the percentage of
cytokine expressing cells. Cytokine production by T lymphocytes
was also determined by flow cytometry, as percentages of cells
expressing cytokines upon stimulation with PMA plus ionomycin
(Sigma Chemical, St Louis, MO, USA) (Rostaing et al, 1999). To
avoid ionophore-induced release of prostaglandins and thrombox-
ane by platelets (Knapp et al, 1977) present in whole-blood
samples, cultures of PBMCs were performed. Briefly, PBMCs were
isolated from heparinised venous blood by density centrifugation
on lympholyte (Cedarlane Labs, Hornby, Canada), as previously
described (Della Bella et al, 2001). The cells were suspended at a
concentration of 1 10
6cellsml
 1 in complete culture medium
consisting of RPMI 1640 supplemented with 10% heat-inactivated
AB human serum, 2mM glutamine, 50Uml
 1 penicillin, 50mgml
 1
streptomycin, in the presence of 10mgml
 1 BFA and in the
presence or absence of 25ngml
 1 PMA and 1mgml
 1 ionomycin.
Cultures were incubated for 18h at 371C in a 5% CO2 humid
atmosphere in a sterile environment. Doses of PMA and
ionomycin and incubation time were optimised in preliminary
experiments. After incubation, the cells were processed for flow
cytometric analysis as described above. The percentage of T
lymphocytes, identified based on the surface expression of CD3,
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4, was evaluated.
Measurement of plasma levels of VEGF, IL-10 and
spermine
Patient and control plasma samples were obtained by centrifuga-
tion of heparinised peripheral blood, and stored at –201C. A
commercial ELISA kit was used to measure plasmatic concentra-
tions of VEGF (R&D Systems, Minneapolis, MN, USA), according
to the manufacturer’s instructions. The IL-10 ELISA was
performed using IL-10-specific mAb 9D7 and biotinylated 12G8
(Endogen, Woburn, MA, USA). Plasmatic spermine concentrations
were determined by reversed-phase high-performance liquid
chromatography after derivatisation with dansyl chloride, as
described (Marchesini et al, 1992).
Effects of spermine on in vitro cultured DCs
Monocyte-derived DCs were generated from the adherent fraction
of PBMCs obtained from healthy control subjects, as described
(Bender et al, 1996). Briefly, PBMCs were allowed to adhere for 2h
in culture flasks, nonadherent cells were gently removed, and the
remaining cells were cultured in RPMI 1640 containing 10% heat-
inactivated FCS (Euroclone, Wetherby, West York, UK) and
supplemented with 800Uml
 1 GM-CSF (Novartis, Italy) and
10ngml
 1 IL-4 (PeproTech, London, UK). Cultures were fed every
other day with fresh medium and cytokines. The effects of
spermine on DC differentiation were examined by adding
spermine (Sigma-Aldrich, St Louis, MO, USA) at the initiation of
culture in parallel cultures. Aminoguanidine was added to cells
along with spermine to inhibit the action of polyamine oxidase.
Concentrations of spermine ranging from 0.5 to 4mM were used,
because these levels were reported to have immunomodulatory
effects (Hasko ` et al, 2000), and were relevant to plasmatic ranges
occurring in our patients. Dendritic cells were collected at day 5.
The immunophenotype of DCs was analysed by three-colour FACS
analysis with 5000–10000 events acquired for each sample.
Endocytosis was assessed by the uptake of FITC-dextran (Sallusto
et al, 1995). Dendritic cells were incubated for 1h at 371C in the
presence of 1mgml
 1 FITC-dextran (70000m.w.; Molecular
Probes, Eugene, OR, USA). Control cells were incubated on ice
for 1h. After extensive washing, the cells were analysed by single-
colour FACS analysis. Results were expressed as the difference
between mean fluorescence intensity (MFI) obtained at 37 and 01C
(negative control). Phagocytosis of apoptotic cells by DCs was
analysed by flow cytometry as reported by Bellone et al (1997) with
some modifications. Briefly, allogeneic monocyte-depleted PBMCs
were labelled with 0.5mM chloro-methyl-fluorescein-diacetate
(CMFDA; Molecular Probes) for 30min at 371C, washed exten-
sively and incubated for 24h in medium supplemented with 10mM
H2O2 to induce apoptosis. Chloro-methyl-fluorescein-diacetate-
labelled apoptotic cells were then incubated with DCs at a ratio of
1:1 at 371C. After 2h, cells were washed and treated with 0.05%
trypsine/0.02% EDTA for 3min to disrupt cell – cell binding.
Phagocytosis was quantified by flow cytometry as the percentage of
CMFDAþ DCs. To evaluate their allostimulatory capacity, DCs
were cocultured for 5 days with allogeneic monocyte-depleted
PBMCs, at a ratio of 1:20. During the last 6h of culture, 20mM 5-
bromo-20-deoxyuridine (BrdU; Sigma Chemical Company, St
Louis, MO, USA) was added, and the proliferation of allogeneic
T lymphocytes was evaluated by flow cytometry as BrdU
incorporation by CD3þ cells, as described by Toba et al. Data
are expressed as the percentage of proliferating BrdUþ T
lymphocytes. IL-12 production was assessed by stimulating
monocyte-derived DCs for 24h with soluble recombinant CD40L
(1mgml
 1; Alexis Biochemicals, San Diego, CA, USA). The IL-12
p70 ELISA was performed using p70-specific mAb 20C2 and
biotinylated C8.6 (Endogen).
Statistical analysis
Comparisons of samples to establish the statistical significance of
difference were determined by the two-tailed Student’s t-test for
independent samples. The paired t-test and the linear regression
analysis were also used when indicated. Results were considered to
be statistically significant when P was p0.05.
RESULTS
Quantitation of PB DCs and DC precursors
The percentage of DCs, identified as Lin-/HLA-DRþ cells, in the
mononuclear cell population was significantly lower in the
peripheral blood of breast cancer patients compared with healthy
controls (breast cancer: 0.8770.04% (mean7s.e.m.) of the
mononuclear cells vs controls: 1.4570.06%; Po0.001). The
number of DCs in the blood, estimated by using the percentages
generated by FACS analysis and the absolute mononuclear cell
count, was also significantly lower in cancer patients than in
controls (19.3771.10 10
3ml
 1 vs 27.7171.59, Po0.001)
(Figure 1). Within the Lin-/HLA-DRþ cells, the percentage of
CD11cþ DCs tended to be lower in cancer patients (49.772.1 vs
54.672.2%, P¼n.s.) and that of CD123þ DCs tended to be higher
(32.171.8 vs 27.571.8%, P¼n.s.). This resulted in a significant
decrease of PB myeloid Lin-/HLA-DRþ/CD11cþ DCs in breast
cancer patients compared with control subjects
(9.6170.68 10
3ml
 1 vs 14.8070.95, Po0.001), while the number
of PB plasmacytoid Lin-/HLA-DRþ/CD123þ DCs was unaffected.
There was no correlation between DC number and tumour size or
stage in patients with invasive breast cancer. The decrease in the
number of DCs in the blood was already apparent, although not
significant, in the few patients with carcinoma in situ included in
the study (20.1772.92 10
3ml
 1), while DC number was un-
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Figure 1 Absolute number of PB DCs in breast cancer patients
compared with controls. A significant decrease in PB Lin-/HLA-DRþ cells
(left axis) and myeloid DCs (right axis) was observed in cancer patients.
Whole blood was stained with a cocktail of FITC-conjugated mAbs
recognising CD3, CD14, CD16, CD19 and CD20, and with PerCP-
conjugated anti-HLA-DR mAb; myeloid DCs were identified as lineage-/
HLA-DRþ/CD11cþ cells, plasmacytoid DCs (right axis) as lineage-/HLA-
DRþ/CD123þ cells. Absolute DC counts were then determined
indirectly by multiplying the percentage of DCs in the mononuclear gate
times the sum of the lymphocyte and monocyte determined on a
differential blood cell counter. Each symbol represents a single sample.
Open circles: control subjects; open triangles: breast cancer patients. Mean
values represented by horizontal lines in each series. P-values were
determined using the t-test for independent samples, patients compared
with controls.
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5.37 10
3ml
 1). The frequency of CD34þ cells in the blood of
cancer patients was significantly higher than in control subjects
(1.1370.32%, n¼7 vs 0.5770.06, n¼12; P¼0.041). Finally, the
frequency of CD14þ monocyte precursors did not differ between
patients and controls (5.8972.02, n¼38, and 6.0670.02, n¼14,
respectively).
Immunophenotype of PB DCs
The activation state of PB DCs, assessed as the expression of the
costimulatory molecules CD80 and CD86 on Lin-/HLA-DRþ cells,
did not significantly differ between patients and controls, although
cancer patients presented a slightly higher percentage of CD80þ
DCs (9.1571.88% of the DCs vs 6.6970.94%) (Figure 2A).
Otherwise, analysis of the maturation state of Lin-/HLA-DRþ
DCs, evaluated as the expression of CD83 molecule, showed that
breast cancer patients had a significantly higher percentage of
mature CD83þ DCs compared with control subjects (5.2370.57
vs 3.0070.75%; P¼0.019). As shown in Figure 2B, DC maturation
appeared correlated to the clinical stage of disease, since the
percentage of CD83þ DCs tended to increase progressively with
the severity of breast cancer (carcinoma in situ: 4.31 7 0.81; stage
I: 4.91 7 2.00; stage IIA: 5.11 7 1.05; stage IIB: 5.46 7 0.83). The
percentage of CD83þ DCs in patients with benign tumours of the
breast was absolutely unaffected (3.07 7 0.92) as compared with
controls. To evaluate the early-maturation stage of DCs, in a few
cases we also analysed DC surface expression of the IFN-g receptor
(CD119), which is progressively down-regulated on maturing DCs
(Kalinski et al, 1999). Breast cancer patients indeed had a
significant lower percentage of CD119þ Lin-/HLA-DRþ DCs
compared with healthy controls (82.00 7 3.63 of the DCs vs 89.92
7 1.85%; P¼0.05).
Effects of LPS stimulation on activation and maturation of
DCs
To assess the ability of PB DCs from breast cancer patients to be
activated following stimulation, we exposed whole-blood samples
to LPS for 5h, and subsequently analysed the expression of
costimulatory molecules and CD83 on DCs. In both patients and
controls, this short-period incubation with LPS induced a
statistically significant increase in the percentage of both
CD80þ Lin-/HLA-DRþ DCs and CD83þ Lin-/HLA-DRþ DCs
(patients and controls: paired t-test Po0.001). LPS also induced an
overexpression of CD86 above the constitutive levels in both the
groups, measured as MFI (patients and controls: paired t-test
Po0.001). The activation and maturation response of DCs to LPS
did not differ between patients and controls, with similar
percentages of CD80þ DCs (patients: 48.43 7 4.78% of DCs vs
controls: 41.17 7 2.90%) and CD83þ DCs (75.94 7 3.17 vs 71.21
7 2.61%), and a similar DC expression of CD86 (MFI: 398.36 7
39.15 vs 349.67 7 27.45%) observed in both the groups in LPS-
exposed blood samples. Incubation of whole-blood samples in
plastic tubes in the presence of culture medium without LPS
induced a slight activation and maturation of DCs, which
emphasised differences between patients and controls, resulting
in significantly higher percentages of CD80þ DCs (9.80 7 1.72 vs
3.86 7 0.77%, P¼0.004) and CD83þ DCs (14.86 7 3.51 vs 4.53
7 1.42%, P¼0.011), and higher DC expression of CD86 (163.14
7 20.33 vs 86.47 7 10.11%, P¼0.028) in breast cancer patients
than in control subjects.
Cytoplasmic cytokine expression in PB DCs
Owing to the central role played by regulatory cytokines produced
by DCs in directing immune responses, we further asked whether
the ability of PB DCs from breast cancer patients to produce
cytokines was impaired. We incubated whole-blood samples
with or without LPS in the presence of BFA for 5h,
and subsequently analysed the expression of intracellular cyto-
kines in unseparated Lin-/HLA-DRþ DCs. In both the groups,
incubation of peripheral blood samples with LPS induced
a significant increase in the percentage of DCs expressing either
IL-12 or IL-10 (patients and controls: paired t-test Po0.001).
As shown in Figure 3, while the unstimulated expression of IL-12
was similar in the two groups, the percentage of DCs expressing
IL-12 upon LPS stimulation was significantly lower in
breast cancer patients than in healthy controls (23.75 7 1.35 vs
34.28 7 1.38%, Po0.001). A representative flow cytometric
analysis is presented in Figure 4. The reduction in IL-12 expression
in cancer patients was also evident when we compared the
mean fluorescence intensity for IL-12 staining in patients
and controls (60.9 7 5.6 vs 86.4 7 11.2%, P¼0.036).
The percentage of DCs expressing cytoplasmic IL-10 was
significantly higher in cancer patients in unstimulated conditions
(3.70 7 0.35 vs 2.65 7 0.22%, P¼0.046), while it was similar
to control subjects upon LPS stimulation. As for the DC count,
the decrease of DCs expressing IL-12 following LPS stimulation
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Figure 2 Immunophenotype of PB DCs. (A) The activation state of Lin-/
HLA-DRþ DCs, assessed as the expression of the costimulatory
molecules CD80 and CD86 (left axis), was similar in patients and controls,
while the frequency of mature DCs was significantly higher in breast cancer
individuals, as assessed by higher percentages of Lin-/HLA-DRþ cells
expressing CD83 (right axis) and lower percentages of Lin-/HLA-DRþ
cells expressing CD119 (left axis). (B) The percentage of mature DCs,
identified as Lin-/HLA-DRþ cells expressing the CD83 maturation marker,
increased progressively with the severity of breast cancer. Each symbol
represents a single sample. Open circles: control subjects; open triangles:
breast cancer patients. Mean values are represented by horizontal lines in
each series. P-values were determined using the t-test for independent
samples, patients compared with controls.
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breast (39.24 7 10.12), and was only slight in patients
with carcinoma in situ (32.28 7 3.39). A significant positive
correlation was observed between the percentage of DCs expres-
sing IL-12 and the percentage of DCs expressing CD119 on
their surface (r¼0.543, n¼13, P¼0.05). No significant correla-
tion was found between cytokine expression by DCs and size or
stage of the tumour, or between the percentages of DCs expressing
IL-12 and IL-10.
Cytoplasmic cytokine expression in T lymphocytes
To assess whether the ability of T lymphocytes from breast cancer
patients to produce cytokines was also affected, we stimulated
PBMCs with PMA and ionomycin in the presence of BFA,
and analysed the intracellular expression of type 1 and type 2
cytokines by CD3þ lymphocytes. In both the groups, incubation
of PBMCs with PMA and ionomycin induced a significant increase
in the percentage of T lymphocytes expressing either IL-4
(patients: paired t-test P¼0.003; controls: Po0.001) or IL-2
(patients and controls: Po0.001) or IFN-g (patients and controls:
Po0.001). As shown in Figure 5A, the percentages of
T lymphocytes expressing cytokines in unstimulated cultures were
low and similar in patients and controls. Upon PMA stimulation,
the percentage of T lymphocytes expressing IL-4 was significantly
higher in breast cancer patients than in controls (2.36 7 0.49 vs
1.37 7 0.16%, P¼0.039), while the percentages of CD3þ cells
expressing either IL-2 or IFN-g were slightly decreased in cancer
patients. Since the balance between type 1 and type 2 cytokines is
thought to be more relevant than absolute values of single
cytokines in driving immune responses, the ratios between
cytokine-expressing lymphocytes were also considered. As shown
in Figure 5B, both the ratio between IL-2þ and IL-4þ
lymphocytes and the ratio between IFN-g þ and IL-4þ
lymphocytes, in PMA-stimulated cultures, were significantly lower
in breast cancer than in control subjects (IL-2/IL-4: 10.06 7 1.61
vs 25.01 7 5.97%, P¼0.049; IFN-g/IL-4: 10.43 7 1.47 vs 21.07 7
4.18%, P¼0.048). No correlation was observed between cytokine
expression by T lymphocytes and DC number or cytokine
expression by DCs.
Effects of surgical removal of the tumour on PB DCs
To assess the impact of surgical resection of the tumour, we
compared PB DCs in seven breast cancer patients before and 4
weeks after the surgery, but prior to adjuvant chemotherapy or
radiation therapy. As shown in Figure 6, removal of the tumour
resulted in normalisation of both the percentage of CD83þ DCs
(pre: 6.06 7 1.08%; post: 3.21 7 0.78%; paired t-test: P¼0.001)
and the percentage of DCs expressing IL-12 upon LPS stimulation
(pre: 21.18 7 3.11%; post: 30.07 7 0.33%; P¼0.042). Removal of
the tumour also induced a decrease, although not significant, of
the percentage of CD80þDCs (pre: 10.52 7 3.53%; post: 6.41 7
1.70%; P¼n.s.). At the time of blood collection, only a partial non-
significant increase of both the proportion of DCs (pre: 0.72 7
0.09% of the mononuclear cell; post: 0.77 7 0.05%) and the
absolute number of myeloid DCs (pre: 9.24 7 2.17 10
3/ml; post:
11.13 7 1.72) was observed.
Correlation between PB DC functions and plasmatic levels
of tumour-derived mediators
To evaluate whether alterations in PB DCs could depend on
tumour-related soluble factors, we analysed the levels of VEGF, IL-
10 and spermine in the plasma of nine patients compared with an
equal number of control subjects. The plasmatic levels of VEGF
(breast cancer: range 31.2 – 177.9pgml
 1; controls: 43.7 – 59.6),
IL-10 (breast cancer: 20.9 – 31.1; controls: 16.9 – 21.7) and
spermine (breast cancer: 0.25 – 4.05; controls: 0.66 – 2.51) did not
significantly differ between groups. However, a significant negative
correlation was found between the plasmatic concentration of
spermine and the percentage of DCs expressing IL-12 upon
stimulation (r¼  0.768, n¼9, P¼0.016). Furthermore, the levels
of spermine tended to be directly correlated with the percentage of
CD83þ DCs, although this correlation did not reach statistical
significance. No correlation was observed between the plasmatic
concentration of VEGF or IL-10 and any DC parameter.
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To evaluate whether spermine could induce alterations in DC
differentiation and function, we cultured monocyte-derived DCs
from healthy donors in the presence or absence of spermine. This
polyamine did not affect the efficiency of generation of DCs from
monocytes, since similar numbers of DCs were obtained in its
presence or absence (data not shown). Preliminary results
obtained from four independent experiments seem to indicate
that exposure of maturing DCs to spermine slightly promotes their
maturation, as assessed by a dose-dependent mild increase of DC
expression of CD83 – at levels similar to those observed in vivo –
and of CD40. The results of immunophenotype analysis are
reported in Figure 7. As illustrated in the same figure, DCs
generated in the presence of spermine showed a reduced capacity
to capture antigens, as assessed by a reduced mannose-receptor-
mediated endocytosis (MFI FITC-dextran, mean7s.e.m. from
428.9 7 81.9 to 315.7 7 86.5%). The reduced capacity of
spermine-conditioned DCs to capture antigens was also measur-
able as reduced phagocytosis of apoptotic cells (% CMFDAþ DCs:
from 18.3 7 2.1 to 11.7 7 2.9%). Moreover, DCs exposed to
spermine exibited a dose-dependent impairment of their allosti-
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Figure 5 Cytokine production by T lymphocytes in breast cancer patients compared with control subjects. PBMCs were cultured in the presence of BFA
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accumulation of cytokines within CD3þ T lymphocytes was evaluated after staining with PE-conjugated mAbs directed against either IL-2 or IFN-g or IL-4.
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ymulatory capacity, as assessed by reduction in the percentage of
BrdUþ proliferating allogenic T lymphocytes on day 5 of culture
(% BrdUþ CD3þ cells: from 11.4 7 2.59 to 7.7 7 2.1%). A
representative experiment is reported in Figure 7. It was possible
that the decrease in T-cell stimulatory function seen for DCs
cultured with spermine reflected the fact that the T-cell division in
these cultures already had peaked, since spermine-conditioned
DCs were more mature and may have activated the T cells more
rapidly. This possibility was excluded by a kinetic study, shown in
Figure 8. Finally, exposure of maturing DCs to spermine partially
inhibited the ability of these cells to produce IL-12 upon
stimulation, as detected by ELISA measurement of the cytokine
in culture supernatants (from 328 7 124 to 181 7 83pgml
 1).
DISCUSSION
In the present study, we evaluated PB DCs in patients with breast
cancer compared with control subjects. We applied flow cyto-
metric methods that allow the enumeration and the immunophe-
notypical as well as functional characterisation of DCs directly in
whole peripheral blood samples (Robinson et al, 1999; Arpinati
et al, 2000; Upham et al, 2000). With this method, we observed that
Lin-/HLA-DRþ DCs are significantly reduced in the peripheral
blood of breast cancer patients compared with healthy donors. The
reduction was already apparent, although not significant, in
patients with in situ breast carcinoma, and was more severe and
statistically significant in patients with invasive carcinoma. Within
the group of invasive breast cancer, which was composed of
patients in the early stage of the disease (I, IIA and IIB), we did not
find a correlation between DC count and stage of cancer. The close
correlation between DC reduction and cancer was emphasised by
the finding that the number of PB DCs was unaffected in the few
women who, following surgical removal, were diagnosed as
affected by benign breast tumour. A similar reduction of Lin-/
HLA-DRþ DCs had been observed by Gabrilovich et al in the
peripheral blood of patients with several malignant neoplasias,
including a group of subjects with breast cancer at various stages,
from I to IV (Almand et al, 2000). Our study confirms and extends
these previous observations, focusing on a larger group of early-
stage breast cancer patients. Furthermore, Gabrilovich et al
estimated blood DC number by extrapolating from the yield of
DCs obtained after multistep purification, while we performed DC
count directly on whole blood, without any ex vivo enrichment.
The results obtained with this procedure, that more directly
reflects the in vivo situation, may corroborate the possible role of
DC alterations in the clinical evolution of malignancies. Together
with the reduction of Lin-/HLA-DRþ DCs, we observed a
statistically significant increase of CD34þ cells in the peripheral
blood of patients with invasive breast cancer. This increase could
be related to tumour-derived factors that may either promote the
mobilisation of CD34þ cells from the bone marrow, such as GM-
CSF (Garrity et al, 1997), or inhibit DC maturation from CD34þ
precursors, such as VEGF, M-CSF and IL-6 (Almand et al, 2000). In
patients with head and neck squamous cell carcinoma, an
increased number of CD34þ progenitor cells endowed with
natural suppressor activity is present in the peripheral blood and
within the tumour tissue (Garrity et al, 1997; Lathers et al, 1999).
To further investigate the significance of the increase of PB
CD34þ cells in breast cancer patients, ongoing studies are
planned to characterise the immunophenotype and the functional
activity of these cells in our patients.
Since human PB DCs can be divided, on the basis of expression
of the b-integrin CD11c (Robinson et al, 1999), into two
subpopulations that differ in the origin, expression of phenotypic
markers, route of activation and immunological activity, we
evaluated their distribution in our patients. We found that the
number of myeloid DCs, and not plasmacytoid DCs, was
significantly decreased in breast cancer patients compared to
controls. This alteration may have a relevant impact on immune
defences against cancer. In fact, CD11cþ myeloid DCs originate
from myeloid bone marrow precursors, express myeloid antigens,
and upon stimulation produce high amounts of IL-12, which in
turn promotes cell-mediated immune responses that are crucial for
the detection and elimination of malignant cells (Cella et al, 1996;
Rissoan et al, 1999; Robinson et al, 1999). CD11c- plasmacytoid
DCs originate from lymphoid bone marrow precursors, lack
myeloid markers, express high levels of the IL-3-receptor-a chain
(CD123) and secrete lower amounts of IL-12 (Rissoan et al, 1999;
Robinson et al, 1999; Reid et al, 2000; Liu et al, 2001). Although it
is now believed that each DC subset has a certain degree of
flexibility in directing T-cell responses (Liu et al, 2001; Shortman
and Liu, 2002), myeloid DCs still remain higher producers of IL-12
than plasmacytoid DCs and key elements in the induction of cell-
mediated immune responses.
Since the presence of costimulatory molecules on DC surface is
crucial in determining whether engaged T lymphocytes will
become anergic or develop productive immunity (Schultz et al,
1996), we evaluated the expression of CD80 and CD86 on Lin-/
HLA-DRþ DCs in our patients, but we did not find significant
differences compared with healthy controls. Since another
important aspect of DC function is the maturation state, we also
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Figure 6 Effects of surgical removal of the tumour on PB DCs. At 4
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maturation marker supposed to be involved in antigen presenta-
tion and cellular interactions (Zhou and Tedder, 1995; Lechmann
et al, 2002). We observed that the percentage of mature CD83þ
DCs is higher in patients with invasive breast cancer compared
with subjects of all other groups (in situ carcinoma, benign breast
neoplasms and healthy controls). Interestingly, CD83þ DCs have
been described in the peritumoral areas of breast cancer samples,
while absent in the normal breast tissue (Bell et al, 1999). We are
planning further studies to investigate the relationships existing
between DCs in peripheral blood and in tumour tissue in our
patients. In normal conditions, PB CD83þ DCs are infrequent
because DC maturation and CD83 expression follow antigen
capture and exposure of DCs to activating stimuli in peripheral
tissues. The high percentage of Lin-/HLA-DRþ DCs expressing
CD83 observed in breast cancer patients could be induced by
tumour-derived factors, as suggested by the observation that the
increased expression of CD83 by PB DCs was completely reverted
in our patients 4 weeks after surgical removal of the tumour.
Moreover, in vitro tumour supernatants are able to promote rapid
maturation of DCs with upregulation of CD83 molecule expression
(Kiertscher et al, 2000). Finally, factors present in the tumour
environment in vivo, such as polyamines or prostaglandins, might
also interfere with the maturation and/or function of DCs (Hasko `
et al, 2000; Harizi et al, 2002). In fact, we found that exposure of in
vitro maturing DCs to spermine enhanced the expression of CD83,
suggesting that this tumour-derived polyamine could be involved
in the phenotypic maturation of PB DCs observed in vivo.
Functional impairment of DCs have also been described in
haematologic diseases, in particular in chronic and acute myeloid
leukaemia, in which defects in antigen processing (Dong et al,
2003) and in allostimulatory activity (Mohty et al, 2001) have been
related to the expression by DCs of the same cytogenetic
abnormalities expressed by freshly isolated leukaemic cells. It
has been suggested that the defects in antigen processing observed
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underlying cytoskeletal changes induced by the expression of the
BCR-ABL fusion gene (Dong et al, 2003). At present, we cannot
exclude the fact that cytoskeletal alterations may similarly
contribute to impaired function of DCs in breast cancer patients.
Owing to the important role of regulatory cytokines of DC origin
in the induction and activation of immune responses, we evaluated
the cytofluorimetric DC expression of IL-12 and IL-10, both in
basal and stimulated conditions. We used LPS as the DC stimulator
because LPS, with or without IFN-g, has been reported to be the
optimal stimulus for analysis of cytokine expression by DCs in
whole-blood samples (Almeida et al, 1999; Bueno et al, 2001), and
because TLR4, which is required for the response to LPS, is
selectively expressed on myeloid CD11cþ DCs (Krug et al, 2001).
We found that DC constitutive production of IL-10 was increased
in patients with invasive cancer, while that of IL-12 was similar to
controls. On the contrary, when we evaluated LPS-induced
expression of cytokines, we observed an impaired expression of
IL-12 by PB DCs from breast cancer patients. The possibility that
the reduction in IL-12-producing cells simply reflects the
reduction in myeloid DCs seems unlikely because the reduction
in the percentage of IL-12-positive DCs largely overcomes the
reduction in the percentage of CD11cþ myeloid DCs. Moreover,
because the reduction of IL-12 expression in our patients is
reversed by tumour excision, we hypothesised that this defect
could be directly dependent on cancer mass and on its
environmental factors, such as polyamines. This possibility is
supported by the inverse correlation existing between plasmatic
levels of spermine and the percentage of PB DCs expressing IL-12
in our patients. The ability of spermine to interfere with IL-12
production seems to be confirmed by our preliminary experiments
on DCs cultured in vitro in the presence of spermine at
concentrations readily achieved in vivo. The impairment of IL-12
production could also be correlated with the increased maturation
state of cancer DCs. In fact, it is known that mature CD83þ DCs
have a reduced IL-12-producing capacity, resulting mainly from
their impaired responsiveness to IFN-g, which is a cofactor in IL-
12 induction (Kalinski et al, 1999). Accordingly, in our study, we
found that the percentage of Lin-/HLA-DRþ DCs expressing IFN-
g receptor (CD119) was significantly reduced in cancer patients.
Furthermore, the percentage of DCs expressing IL-12 was directly
correlated with the percentage of DCs expressing CD119 on their
surface. The reduced capacity of PB DCs to express IL-12 upon LPS
in vitro stimulation in our breast cancer patients was specific for
this cytokine, and could not be ascribed to a general hyporespon-
siveness of these cells to LPS. In fact, LPS-induced upregulation of
CD80, CD86 and CD83, and the expression of IL-10 were similar in
cancer patients and healthy controls.
A perturbation of the cytokine network characterised by low
levels of IL-12 and normal or high levels of IL-10 has been
previously reported in patients with neoplasms of various organs
(O’Hara et al, 1998; Jacobs et al, 1998; Merendino et al, 1999); it
has been suggested that this imbalance in IL-12 and IL-10 levels
could explain the shift from type 1 to type 2 cytokine production
by T lymphocytes known to occur in cancer patients (Ela ¨sser-Beile
et al, 1993; Clerici et al, 1994; Clerici et al, 1997, 1998). Actually, we
found that T-helper lymphocytes from our cancer patients were
polarised towards the Th2 phenotype, suggesting that altered
production of regulatory cytokines by DCs may affect adaptive
immune responses.
In summary, our results seem to suggest that breast cancer
affects DC maturation following two pathways. The first one could
affect early stages of DC differentiation and could be responsible
for the increased frequency of CD34þ cells and decreased number
of Lin-/HLA-DRþ DCs observed in the peripheral blood of breast
cancer patients (Almand et al, 2000). The second pathway could
affect later stages of DC differentiation, and could be responsible
for the shift to a mature-like phenotype and for the impaired IL-12
production by PB DCs. We suggest that these two mechanisms
could concomitantly act in breast cancer to prevent the establish-
ment of an effective antitumour immune response.
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